78.89MMarket Cap-3598P/E (TTM)
1.080High1.030Low94.83KVolume1.080Open1.040Pre Close100.34KTurnover0.13%Turnover RatioLossP/E (Static)75.85MShares2.62052wk High4.75P/B75.53MFloat Cap0.88352wk Low--Dividend TTM72.62MShs Float7.400Historical High--Div YieldTTM4.81%Amplitude0.351Historical Low1.058Avg Price1Lot Size
Oncolytics Biotech Stock Forum
MT Newswires· 12 mins ago
07:00 AM EDT, 06/27/2024 (MT Newswires) -- Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech has dosed the first patient in the GOBLET study cohort, which assesses the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The study, funded by a US$5 million grant from PanCAN’s Therapeutic Accelerator Awar...
Following discussions with the clinical advisors, collaborators, and potential partners over the last year, Oncolytics aims to conduct an "efficiently sized," cost-effective, randomized, controlled study that with positive data could lead directly to a...
NEWS
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech Inc. has received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRINOX and an anti-PD-L1 inhibitor in pancreatic cancer. The company will start enrollment in a new GOBLET study cohort, supported by a $5M grant from PanCAN, with the first patient expecte...
Benzinga· 3 mins ago
This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). "We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a tr...
NEWS
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Oncolytics Biotech Inc. announces a Type C meeting request with the FDA for a registration-enabling trial in HR+/HER2- metastatic breast cancer. Positive results from the BRACELET-1 trial and upcoming overall survival data in H2 2024 indicate a transformative year ahead.
No comment yet